결합제 및 부형제 시장 : 세계 예측(2026-2032년)

The Binders Excipients Market is projected to grow by USD 4.24 billion at a CAGR of 9.94% by 2032.

Binders excipients are essential functional ingredients used to impart cohesiveness, mechanical strength, and manufacturability to tablets, granules, capsules, and other solid dosage forms. In pharmaceutical formulation, commonly used binders include cellulose derivatives, starches, povidone, polyethylene glycols, gelatin, sugars, gums, and coprocessed excipient systems. Their role extends beyond particle adhesion: binder selection influences tablet hardness, friability, disintegration, dissolution behavior, process robustness, moisture sensitivity, and compatibility with active pharmaceutical ingredients. As oral solid dosage forms remain central to global drug delivery due to patient convenience, scalability, and established regulatory pathways, binder excipients continue to be critical to product quality and lifecycle management.

The binder excipients landscape is shaped by rising demand for high-performance excipients that support direct compression, wet granulation, dry granulation, continuous manufacturing, and modified-release systems. Regulatory expectations for excipient quality, traceability, impurity control, and documentation are increasing, particularly as supply chains become more globalized. At the same time, pharmaceutical manufacturers are prioritizing reliable sourcing, sustainable raw materials, multifunctional excipients, and formulation platforms that reduce development timelines. These dynamics position binder excipients as strategic formulation enablers rather than commodity ingredients.

Transformative Shifts in the Binders Excipients Landscape

The binders excipients landscape is undergoing significant transformation as pharmaceutical manufacturers move toward more efficient, quality-driven, and patient-centric formulation strategies. One of the most important shifts is the growing adoption of direct compression and continuous manufacturing, both of which require binders with consistent particle morphology, compressibility, flowability, and batch-to-batch performance. This has increased interest in coprocessed and multifunctional excipients that combine binding, filler, disintegrant, and flow-enhancing properties within a single material platform.

Another major shift is the heightened focus on regulatory compliance and excipient risk management. Manufacturers are increasingly expected to demonstrate robust supplier qualification, good distribution practices, elemental impurity assessment, nitrosamine risk evaluation where relevant, and alignment with pharmacopeial standards. Sustainability is also influencing procurement and product development, with plant-derived, renewable, low-residue, and clean-label excipients gaining attention across pharmaceutical, nutraceutical, and healthcare applications. In parallel, the growth of complex generics, pediatric and geriatric dosage forms, orally disintegrating tablets, and modified-release products is expanding the technical requirements placed on binder systems. These shifts are elevating binder excipients from traditional processing aids to critical contributors to therapeutic performance, manufacturing resilience, and regulatory confidence.

Cumulative Impact of Artificial Intelligence on Binders Excipients

Artificial intelligence is beginning to influence binder excipient selection, formulation development, process optimization, and quality assurance. In formulation design, AI-enabled models can analyze historical formulation datasets, material attributes, process parameters, and performance outcomes to identify excipient combinations that improve compressibility, dissolution, tablet strength, and manufacturability. This is particularly relevant for binders, where performance depends on interactions among particle size distribution, moisture content, viscosity, glass transition behavior, deformation characteristics, and active ingredient properties.

AI also supports quality-by-design approaches by accelerating design-of-experiments planning, predicting failure modes, and identifying critical material attributes linked to tablet defects such as capping, lamination, sticking, and friability. In manufacturing, machine learning models can monitor granulation endpoint, compression force, tablet weight variation, and hardness trends in near real time, helping reduce process variability. In supply chain management, AI-driven analytics can flag supplier risk, raw material variability, documentation gaps, and logistics disruptions. While AI does not replace laboratory validation, pharmacopeial testing, or regulatory evidence, it can shorten development cycles, enhance formulation robustness, and improve knowledge management across binder excipient workflows.

Key Regional Insights for Binders Excipients

Asia-Pacific is increasingly important for binders excipients due to expanding pharmaceutical manufacturing capacity, strong generic drug production, and rising demand for affordable oral solid dosage forms across China, India, Japan, South Korea, Australia, and ASEAN economies. Regional producers benefit from established chemical, starch, cellulose, and polymer supply chains, while regulatory harmonization efforts and investments in quality systems are improving global export readiness. North America remains a highly regulated and innovation-oriented region, with strong emphasis on advanced formulation development, excipient qualification, continuous manufacturing, and resilient sourcing for essential medicines. Demand in the United States and Canada is closely connected to complex generics, specialty formulations, nutraceuticals, and high standards for documentation and supplier transparency.

Latin America shows steady relevance as local pharmaceutical production and generic medicine access programs support demand for reliable binder excipients in countries such as Brazil and Mexico. The region's priorities include cost-effective formulation inputs, import reliability, and compliance with evolving health authority requirements. Europe is characterized by stringent regulatory expectations, mature pharmaceutical manufacturing, and strong adoption of sustainable and high-quality excipient systems. The European market places particular emphasis on pharmacopeial compliance, environmental responsibility, traceability, and formulation performance in both branded and generic medicines. The Middle East is strengthening its pharmaceutical manufacturing base through localization initiatives, healthcare infrastructure development, and procurement diversification, which supports demand for excipients used in essential and chronic disease medicines. Africa is an emerging opportunity area where pharmaceutical localization, improved medicine access, and regional manufacturing initiatives are increasing attention on stable, affordable, and quality-assured binder excipients suited to varied climate and logistics conditions.

Key Group Insights for Binders Excipients

ASEAN is gaining strategic relevance in binders excipients as regional pharmaceutical production expands and member economies strengthen regulatory collaboration, manufacturing standards, and access to generic medicines. The region's diverse manufacturing base creates demand for binders that support conventional tablets, nutraceuticals, and cost-efficient formulations while meeting rising expectations for quality and documentation. The GCC is focused on pharmaceutical localization, supply security, and healthcare self-sufficiency, making excipient sourcing an important part of industrial policy and procurement planning. Binder excipients in GCC markets are increasingly tied to local dosage form manufacturing, chronic disease therapies, and partnerships that improve technical capabilities.

The European Union remains a benchmark for excipient governance due to its rigorous quality, safety, and traceability requirements, including expectations related to good manufacturing practice assessment for excipients, pharmacopeial compliance, and supplier qualification. BRICS economies play a prominent role in pharmaceutical production and consumption, with China and India contributing major manufacturing capacity, Brazil and Russia supporting regional demand, and South Africa serving as a gateway for African healthcare supply chains. These countries prioritize affordable medicines, local production, and dependable raw material access. G7 countries continue to shape advanced pharmaceutical development, regulatory science, and excipient innovation through strong research ecosystems and stringent quality expectations. NATO member countries, while not a pharmaceutical trade bloc, are increasingly attentive to medical supply chain resilience, essential medicine availability, and secure sourcing, factors that indirectly support demand for dependable binder excipient supply networks in allied healthcare systems.

Key Country Insights for Binders Excipients

The United States is a leading center for advanced formulation development, complex generics, continuous manufacturing adoption, and stringent excipient qualification, making binder performance, documentation, and supply reliability central purchasing criteria. Canada emphasizes high-quality pharmaceutical and nutraceutical production, with demand linked to regulatory compliance and stable access to excipients for oral solid dosage forms. Mexico benefits from its role in regional pharmaceutical manufacturing and healthcare access programs, supporting demand for cost-effective binders used in generic medicines and over-the-counter products. Brazil is a major Latin American pharmaceutical producer where local manufacturing, public health procurement, and generic medicine use drive interest in reliable excipient supply and regulatory alignment.

The United Kingdom maintains strong pharmaceutical research and manufacturing capabilities, with binder excipient demand shaped by innovation in solid dosage forms, high-quality generics, and post-Brexit supply chain management. Germany is a major European pharmaceutical and chemical manufacturing hub, emphasizing excipient quality, technical performance, sustainability, and compliance with European standards. France supports demand through established medicine production, regulatory rigor, and interest in patient-friendly dosage forms. Russia's pharmaceutical localization policies and domestic production priorities support demand for binders used in essential medicines, although supply chain complexity and regulatory adaptation remain important considerations. Italy and Spain maintain strong generic and contract manufacturing activity, creating demand for binders that support efficient tablet production, robust granulation, and compliance with European pharmacopeial expectations.

China is central to global excipient production and pharmaceutical manufacturing, with demand driven by generic medicines, regulatory modernization, and growing emphasis on higher-quality excipient standards. India is a major supplier of generic medicines and finished dosage forms, making binder excipients essential for scalable, cost-efficient tablet manufacturing and export-oriented compliance. Japan prioritizes high-quality pharmaceutical products, patient-centric dosage forms, and strict quality expectations, supporting demand for consistent and well-characterized binders. Australia's pharmaceutical and nutraceutical sectors rely on quality-assured excipients, with demand influenced by regulatory compliance and consumer health products. South Korea combines advanced pharmaceutical manufacturing, bioscience investment, and export ambitions, increasing the importance of binder systems that meet international quality and performance requirements.

Actionable Recommendations for Binders Excipients Industry Leaders

Industry leaders should prioritize excipient quality systems, supplier diversification, and formulation performance data to strengthen resilience in the binders excipients value chain. A practical first step is to build robust supplier qualification programs that assess pharmacopeial compliance, manufacturing controls, impurity profiles, change notification practices, and documentation quality. Companies should avoid overdependence on single-source materials and develop validated alternate suppliers where technically feasible, particularly for widely used cellulose, starch, povidone, and polymer-based binders.

Formulation teams should invest in deeper material characterization, including particle size, bulk density, moisture content, viscosity, compressibility, thermal behavior, and compatibility with active ingredients. Integrating quality-by-design principles can improve process robustness and reduce development delays. Manufacturers should also evaluate multifunctional and coprocessed binders where they can simplify formulations, improve tabletability, or support direct compression. Sustainability should become part of procurement and innovation strategies through responsible sourcing, waste reduction, solvent minimization, and preference for renewable or lower-impact materials when performance and regulatory requirements are met. Finally, organizations should use digital tools and AI-supported analytics to improve formulation knowledge management, monitor supplier risk, and optimize manufacturing parameters without compromising laboratory verification or regulatory validation.

Research Methodology for Binders Excipients Insights

This executive summary is developed using a structured secondary research methodology focused on verified and data-backed industry knowledge. The research approach includes review of pharmacopeial references, regulatory guidance, excipient quality frameworks, pharmaceutical manufacturing practices, scientific literature, trade documentation, and publicly available healthcare and industrial policy sources. Emphasis is placed on technical attributes of binder excipients, regulatory requirements, regional pharmaceutical manufacturing dynamics, and validated trends in formulation science.

The analysis avoids unverified projections, market sizing, market share claims, and speculative forecasts. Insights are synthesized through cross-validation of multiple credible source categories, including regulatory agencies, pharmacopeial bodies, peer-reviewed formulation research, industry standards, and public health manufacturing policy references. Regional, group, and country-level insights are interpreted based on known pharmaceutical production capabilities, regulatory maturity, medicine access priorities, and supply chain considerations. The methodology prioritizes relevance to decision-makers in excipient manufacturing, pharmaceutical formulation, procurement, quality assurance, and regulatory affairs.

Conclusion: Strategic Outlook for Binders Excipients

Binders excipients remain indispensable to pharmaceutical formulation because they directly influence manufacturability, tablet integrity, dissolution performance, and patient-ready dosage quality. The sector is evolving through stronger regulatory expectations, growth in direct compression and continuous manufacturing, rising demand for multifunctional excipients, and increasing attention to sustainable and resilient supply chains. Artificial intelligence is adding value by improving formulation screening, process monitoring, and supplier risk intelligence, although empirical testing and regulatory validation remain essential.

Regional dynamics show a balanced global landscape: Asia-Pacific is strengthening manufacturing depth, North America and Europe continue to lead in quality and innovation expectations, Latin America is supported by generic medicine access, and the Middle East and Africa are gaining relevance through localization and healthcare capacity building. For industry leaders, success will depend on technical differentiation, quality assurance, diversified sourcing, digital readiness, and the ability to align binder excipient performance with evolving dosage form needs. Organizations that treat binders as strategic formulation assets rather than basic processing aids will be better positioned to support reliable, compliant, and patient-focused pharmaceutical products.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Binders Excipients Market, by Type

• 7.1. Introduction
• 7.2. Natural Binders
  • 7.2.1. Starch
  • 7.2.2. Cellulose
  • 7.2.3. Gum
  • 7.2.4. Gelatin
  • 7.2.5. Alginate
  • 7.2.6. Chitosan
• 7.3. Synthetic Binders
  • 7.3.1. Polyvinylpyrrolidone (PVP)
  • 7.3.2. Polyethylene Glycol (PEG)
  • 7.3.3. Acrylic Polymer Binders
  • 7.3.4. Methacrylate Copolymers

8. Binders Excipients Market, by Form

• 8.1. Introduction
• 8.2. Dry Binder
• 8.3. Liquid Binder

9. Binders Excipients Market, by Grade

• 9.1. Introduction
• 9.2. Nutraceutical
• 9.3. Pharmaceutical

10. Binders Excipients Market, by Application

• 10.1. Introduction
• 10.2. Direct Compression
• 10.3. Dry Granulation
• 10.4. Oral Solid Dosage
  • 10.4.1. Capsule
  • 10.4.2. Tablet
• 10.5. Wet Granulation

11. Binders Excipients Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Binders Excipients Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Binders Excipients Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Asahi Kasei Corporation
• 15.2. Ashland Global Holdings Inc.
• 15.3. BASF SE
• 15.4. BENEO GmbH
• 15.5. Cargill, Incorporated
• 15.6. CD Formulation
• 15.7. Colorcon, Inc.
• 15.8. Croda International PLC
• 15.9. DFE Pharma GmbH & Co KG
• 15.10. DuPont de Nemours Inc.
• 15.11. Eastman Chemical Company
• 15.12. Evonik Industries AG
• 15.13. Fuji Chemical Industries Co., Ltd.
• 15.14. IMCD Group B.V.
• 15.15. International Flavors & Fragrances Inc.
• 15.16. IOI Oleo GmbH
• 15.17. JRS PHARMA GmbH + Co. KG
• 15.18. Kline & Company
• 15.19. Merck KGaA
• 15.20. NIPPON SODA CO., LTD.
• 15.21. Roquette Freres SA
• 15.22. RUIBANG
• 15.23. Sudzucker AG
• 15.24. The Dow Chemical Company
• 15.25. Tomita Pharmaceutical Co., Ltd.